Immunome, Inc. (IMNM)

In the past six months, Immunome's stock has been impacted by several events, including the release of Q1 and Q2 2025 financial results. Preclinical data on its ADC payload HC74 was presented in October 2025. Goldman Sachs and Craig-Hallum initiated coverage of Immunome with a "Buy" recommendation. A collaboration with Infinimmune for antibody discovery and optimization was announced in September 2025. The company announced the dosing of the first patient in the Phase 1 trial of IM-1021 and provided updates on the ongoing study. Topline data for the Phase 3 RINGSIDE trial of varegacestat is expected in the second half of 2025. Immunome reported inducement grants under Nasdaq Listing Rule 5635(c)(4) in September and October 2025.

As a clinical-stage biotechnology company, Immunome, Inc. does not have commercial products or services that would exhibit traditional demand seasonality. The company's revenue is primarily generated through strategic collaborations and licensing agreements, rather than product sales. Therefore, demand seasonality for Immunome is not applicable in the conventional sense. Instead, the company's financial performance and investor interest are driven by progress in its clinical pipeline, regulatory milestones, preclinical data readouts, and strategic partnerships.

Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody therapeutics for oncology and infectious diseases, operating within the biotechnology sector. The company leverages a human memory B cell platform to identify novel therapeutic antibodies and their targets. Its pipeline includes Varegacestat, a gamma secretase inhibitor in Phase 3 trial for desmoid tumors; IM-1021, a ROR1-targeted antibody-drug conjugate in Phase 1 trial for advanced B-cell lymphomas and solid tumors; IM-3050, a FAP-targeted radioligand therapy with an IND application expected in Q1 2025; preclinical ADCs like IM-1617, IM-1335, and IM-1340; and earlier-stage oncology candidates IMM-ONC-01 and IMM-ONC-02.

Immunome, Inc. is headquartered in Bothell, Washington, and was originally founded in Exton, Pennsylvania. While its primary operational base appears to be in the United States, the company aims to establish a global presence through partnerships and collaborations in key markets. Immunome has a worldwide collaboration with AbbVie for the discovery of novel oncology targets. Clinical trials for its drug candidates, such as the Phase 1 trial for IM-1021, are multicenter studies.

Immunome's brand reputation in the past year appears to be largely positive, driven by its innovative approach to cancer therapy and strategic advancements. The company has received a consensus rating of "Moderate Buy" from analysts. Analyst coverage initiations from Goldman Sachs and Craig-Hallum with "Buy" ratings highlight a positive outlook and perceived growth potential. The company's strategic collaborations contribute to a positive perception within the industry. Immunome's focus on developing first-in-class and best-in-class targeted cancer therapies enhances its reputation.

Immunome is predominantly owned by institutional shareholders (91.25%), with insiders holding 7.71% and retail investors 1.03%. Major institutional owners include T. Rowe Price Investment Management Inc., FMR LLC, BlackRock, Inc., Redmile Group, LLC, Enavate Sciences GP, LLC, Point72 Asset Management, L.P., and Vanguard Group Inc. The largest individual shareholder is Isaac Barchas, owning 3.26% of the company.